Top-rated drug stocks Jazz Pharmaceuticals, United Therapeutics and Questcor Pharmaceuticals all missed fourth-quarter sales estimates Tuesday, sending their shares down significantly. Jazz (JAZZ) reported revenue of $236 million, up 28% from a year earlier but about $2 million below analysts’ consensus. Profit minus one-time items also came up short at $1.72 a share, 6 cents below estimates but up 12% from the prior year. CFO
Specialty drugmaker Jazz Pharmaceuticals (JAZZ) hit another new high in the stock market today as the company prepared to deliver its Q4 earnings report after the market close on Tuesday. Analysts polled by Thomson Reuters estimate that the quarter’s profit totaled $1.78 a share, up 16% from the year-earlier quarter. Sales were estimated to rise 30% to $238 million. The outlook for the coming year will likely be of greatest interest to Wall
With earnings season winding down, only a handful of leading stocks have yet to report results, but Valeant Pharmaceuticals (VRX) and Jazz Pharmaceuticals (JAZZ) could give investors a late-season lift. Jazz, Valeant and Amira Nature Foods (ANFI) are the IBD 50 stocks set to provide quarterly results this week. Jazz is No. 4 on the IBD 50 and is on tap to report financials Tuesday. It’s grown in part by buying other drugmakers. Wall Street liked